EU Pharmaceutical Legislation Reform

The EU’s overhaul of pharmaceutical legislation signals a pivotal shift for companies navigating regulatory data protection (RDP) and market exclusivity. This reform aims to balance patient access with innovation, introducing shorter data protection periods with possible extensions for incentivized innovation, keeping the EU competitive with U.S. and Japanese models.